Related Experiment Video
Updated: Apr 8, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm
Abstract:
Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal malignancies, exhibits a 5-year survival rate below 10% and extremely poor clinical prognosis. Over 90% of PDAC patients harbor KRAS gene driver mutations, which promote tumor proliferation, invasion, and immunosuppression of the tumor microenvironment through constitutive activation of downstream RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways. Although the therapeutic potential of targeting KRAS has been recognized for decades, its smooth protein structure and lack of traditional drug-binding pockets led to its long-standing classification as an "undruggable" target, resulting in limited efficacy of early targeted agents. Recent breakthroughs with next-generation KRAS inhibitors have transformed the therapeutic landscape for pancreatic cancer. This review synthesizes evidence from basic research and clinical translation to provide a theoretical foundation and practical guidance for the precision treatment of KRAS-mutant pancreatic cancer.
Insights
Next-generation KRAS inhibitors offer new hope for pancreatic cancer patients. This review details precision treatment strategies for KRAS-mutant pancreatic ductal adenocarcinoma, improving survival rates.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a poor prognosis.
- Over 90% of PDAC cases are driven by KRAS mutations, activating key signaling pathways.
- KRAS was historically considered
- undruggable
- due to its structure, limiting treatment options.
Purpose of the Study:
- To review the latest advancements in targeting KRAS mutations in pancreatic cancer.
- To provide a foundation for precision treatment of KRAS-mutant PDAC.
- To synthesize research and clinical data for therapeutic guidance.
Main Methods:
- Literature review of basic research and clinical trials.
- Analysis of KRAS signaling pathways in PDAC.
- Evaluation of next-generation KRAS inhibitors.
Main Results:
- Recent breakthroughs have yielded effective KRAS inhibitors.
- Targeting KRAS transforms the therapeutic landscape for pancreatic cancer.
- Precision medicine approaches are emerging for KRAS-mutant PDAC.
Conclusions:
- Next-generation KRAS inhibitors represent a significant advance in PDAC treatment.
- Precision treatment strategies are crucial for managing KRAS-mutant pancreatic cancer.
- This review offers guidance for the clinical application of these novel therapies.
